Toxoplasmosis - Pipeline Review, H1 2020
Toxoplasmosis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H1 2020, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H1 2020, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Toxoplasmosis - Overview
Toxoplasmosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Toxoplasmosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toxoplasmosis - Companies Involved in Therapeutics Development
AbbVie Inc
GlaxoSmithKline Plc
Tiba Biotech LLC
Vaxinano SE
Vyera Pharmaceuticals LLC
Toxoplasmosis - Drug Profiles
fanotaprim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Ocular Toxoplasmosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine formulation I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Toxoplasmosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis [type II delta KU80 RH strain] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRP-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUR-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toxoplasmosis - Dormant Projects
Toxoplasmosis - Product Development Milestones
Featured News & Press Releases
Apr 15, 2020: Oakrum Pharma announces the launch of Toxo Total Care patient services program to support Pyrimethamine 25mg tablets
Mar 31, 2020: Optime Care announces availability Of 25mg Pyrimethamine tablets for patients diagnosed with toxoplasmosis
Mar 11, 2020: Oakrum Pharma announces the launch of Pyrimethamine 25mg tablets in the United States
Feb 03, 2020: FDA grants approval of Daraprim drug’s first generic to Cerovene
Jan 27, 2020: FTC and NY Attorney General charge Vyera Pharmaceuticals, Martin Shkreli, and other defendants with anticompetitive scheme to protect a list-price increase of more than 4,000 percent for life-saving drug Daraprim
Nov 15, 2018: Vyera Pharmaceuticals receives FDA clearance to initiate a phase 1 study Of a new chemical entity designed as a potential treatment For toxoplasmosis
Feb 08, 2018: Vyera Pharmaceuticals Has Initiated a Phase 1 Study of a New Dihydrofolate Reductase Inhibitor Designed as a Potential Treatment for Toxoplasmosis
Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee
Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing
Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)
Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary
Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability
Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging
Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction
Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Toxoplasmosis - Overview
Toxoplasmosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Toxoplasmosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toxoplasmosis - Companies Involved in Therapeutics Development
AbbVie Inc
GlaxoSmithKline Plc
Tiba Biotech LLC
Vaxinano SE
Vyera Pharmaceuticals LLC
Toxoplasmosis - Drug Profiles
fanotaprim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Ocular Toxoplasmosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrimethamine formulation I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Toxoplasmosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis [type II delta KU80 RH strain] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toxoplasmosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRP-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUR-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toxoplasmosis - Dormant Projects
Toxoplasmosis - Product Development Milestones
Featured News & Press Releases
Apr 15, 2020: Oakrum Pharma announces the launch of Toxo Total Care patient services program to support Pyrimethamine 25mg tablets
Mar 31, 2020: Optime Care announces availability Of 25mg Pyrimethamine tablets for patients diagnosed with toxoplasmosis
Mar 11, 2020: Oakrum Pharma announces the launch of Pyrimethamine 25mg tablets in the United States
Feb 03, 2020: FDA grants approval of Daraprim drug’s first generic to Cerovene
Jan 27, 2020: FTC and NY Attorney General charge Vyera Pharmaceuticals, Martin Shkreli, and other defendants with anticompetitive scheme to protect a list-price increase of more than 4,000 percent for life-saving drug Daraprim
Nov 15, 2018: Vyera Pharmaceuticals receives FDA clearance to initiate a phase 1 study Of a new chemical entity designed as a potential treatment For toxoplasmosis
Feb 08, 2018: Vyera Pharmaceuticals Has Initiated a Phase 1 Study of a New Dihydrofolate Reductase Inhibitor Designed as a Potential Treatment for Toxoplasmosis
Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee
Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing
Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)
Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary
Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability
Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging
Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction
Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Toxoplasmosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Toxoplasmosis - Pipeline by AbbVie Inc, H1 2020
Toxoplasmosis - Pipeline by GlaxoSmithKline Plc, H1 2020
Toxoplasmosis - Pipeline by Tiba Biotech LLC, H1 2020
Toxoplasmosis - Pipeline by Vaxinano SE, H1 2020
Toxoplasmosis - Pipeline by Vyera Pharmaceuticals LLC, H1 2020
Toxoplasmosis - Dormant Projects, H1 2020
Number of Products under Development for Toxoplasmosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Toxoplasmosis - Pipeline by AbbVie Inc, H1 2020
Toxoplasmosis - Pipeline by GlaxoSmithKline Plc, H1 2020
Toxoplasmosis - Pipeline by Tiba Biotech LLC, H1 2020
Toxoplasmosis - Pipeline by Vaxinano SE, H1 2020
Toxoplasmosis - Pipeline by Vyera Pharmaceuticals LLC, H1 2020
Toxoplasmosis - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Toxoplasmosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
AbbVie Inc
GlaxoSmithKline Plc
Tiba Biotech LLC
Vaxinano SE
Vyera Pharmaceuticals LLC
Number of Products under Development for Toxoplasmosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
COMPANIES MENTIONED
AbbVie Inc
GlaxoSmithKline Plc
Tiba Biotech LLC
Vaxinano SE
Vyera Pharmaceuticals LLC
